ORYZON GENOMICS SA
A Healthtech startup included in the Barcelona & Catalonia Startup Hub

ORYZON
EXIT
ORYZON is a clinical stage biopharmaceutical company that discovers and develops innovative epigenetics-based therapeutics for patients with cancer and neurodegenerative disorders. We are able to identify biomarkers through our genomics and proteomics platforms and to translate them in advanced and personalized therapies.
Industries & Technologies
Financial data
Other information
Funding
(December 2015)
IPO
Investors: n.a.
17M € (October 2015)
Minority stake unknown 6,5%
Investors: CORPORACION SANT BERNAT SCR SA, LABORATORIOS ORDESA SL
Source: Press releases newsletters & platforms company websites annual reports & accounts regulatory body sites & stock exchanges
Other startups near startup ORYZON
similar companies
Collaborators of Barcelona & Catalonia Startup Hub.
We teamed up with business associations, universities and startup incubators to create the Barcelona & Catalonia Startup Hub.